The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-β-mediated antiviral activity in vitro and in vivo

Rapid Selection of Oseltamivir‐ and Peramivir‐Resistant Pandemic H1N1 Virus during Therapy in 2 Immunocompromised Hosts

(2010) Matthew J. Memoli et al.   CLINICAL INFECTIOUS DISEASES

Pegylated Interferons for the Treatment of Chronic Hepatitis C

(2010) Graham R. Foster   DRUGS

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities

(2010) Michelle Head et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa

(2009) Aeron C. Hurt et al.   ANTIVIRAL RESEARCH

Peginterferon-α-2a (40 kD)

(2009) Gillian M. Keating   DRUGS

Costimulation Modulation Uncouples Protection from Immunopathology in Memory T Cell Responses to Influenza Virus

(2009) J. R. Teijaro et al.   JOURNAL OF IMMUNOLOGY

Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo

(2009) Q M Nhu et al.   Mucosal Immunology

The Emergency Use Authorization of Peramivir for Treatment of 2009 H1N1 Influenza

(2009) Debra Birnkrant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Global Transmission of Oseltamivir-Resistant Influenza

(2009) Anne Moscona   NEW ENGLAND JOURNAL OF MEDICINE

Emergence of Oseltamivir-Resistant Pandemic H1N1 Virus during Prophylaxis

(2009) Mariana Baz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid in Cancer Patients

(2008) J. Li et al.   CLINICAL CANCER RESEARCH

Adjuvant therapy of melanoma with interferon: lessons of the past decade

(2008) Paolo A Ascierto et al.   Journal of Translational Medicine